Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 3
2001 3
2002 5
2003 4
2004 5
2005 4
2006 6
2007 8
2008 7
2009 4
2010 6
2011 3
2012 7
2013 14
2014 7
2015 5
2016 7
2017 12
2018 13
2019 6
2020 5
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 22439931

122 results
Results by year
Filters applied: . Clear all
Page 1
Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.
Su L, Sampaio AV, Jones KB, Pacheco M, Goytain A, Lin S, Poulin N, Yi L, Rossi FM, Kast J, Capecchi MR, Underhill TM, Nielsen TO. Su L, et al. Cancer Cell. 2012 Mar 20;21(3):333-47. doi: 10.1016/j.ccr.2012.01.010. Cancer Cell. 2012. PMID: 22439931 Free PMC article.
Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.
Carmody Soni EE, Schlottman S, Erkizan HV, Uren A, Toretsky JA. Carmody Soni EE, et al. Clin Orthop Relat Res. 2014 Mar;472(3):874-82. doi: 10.1007/s11999-013-3065-9. Clin Orthop Relat Res. 2014. PMID: 23716114 Free PMC article.
The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.
McBride MJ, Pulice JL, Beird HC, Ingram DR, D'Avino AR, Shern JF, Charville GW, Hornick JL, Nakayama RT, Garcia-Rivera EM, Araujo DM, Wang WL, Tsai JW, Yeagley M, Wagner AJ, Futreal PA, Khan J, Lazar AJ, Kadoch C. McBride MJ, et al. Cancer Cell. 2018 Jun 11;33(6):1128-1141.e7. doi: 10.1016/j.ccell.2018.05.002. Epub 2018 May 31. Cancer Cell. 2018. PMID: 29861296 Free PMC article.
SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M, Sievers E, Aretz S, Kindler D, Michels S, Friedrichs N, Renner M, Kirfel J, Steiner S, Huss S, Koch A, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Waha A, Schirmacher P, Mechtersheimer G, Wardelmann E, Büttner R, Hartmann W. Trautmann M, et al. Oncogene. 2014 Oct 16;33(42):5006-16. doi: 10.1038/onc.2013.443. Epub 2013 Oct 28. Oncogene. 2014. PMID: 24166495
Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Lubieniecka JM, de Bruijn DR, Su L, van Dijk AH, Subramanian S, van de Rijn M, Poulin N, van Kessel AG, Nielsen TO. Lubieniecka JM, et al. Cancer Res. 2008 Jun 1;68(11):4303-10. doi: 10.1158/0008-5472.CAN-08-0092. Cancer Res. 2008. PMID: 18519690 Free article.
SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas.
Jones KB, Su L, Jin H, Lenz C, Randall RL, Underhill TM, Nielsen TO, Sharma S, Capecchi MR. Jones KB, et al. Oncogene. 2013 May 2;32(18):2365-71, 2375.e1-5. doi: 10.1038/onc.2012.247. Epub 2012 Jul 16. Oncogene. 2013. PMID: 22797074 Free PMC article.
Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.
Yoneda Y, Ito S, Kunisada T, Morimoto Y, Kanzaki H, Yoshida A, Shimizu K, Ozaki T, Ouchida M. Yoneda Y, et al. PLoS One. 2013 Oct 9;8(10):e77564. doi: 10.1371/journal.pone.0077564. eCollection 2013. PLoS One. 2013. PMID: 24130893 Free PMC article.
The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation.
de Bruijn DR, Allander SV, van Dijk AH, Willemse MP, Thijssen J, van Groningen JJ, Meltzer PS, van Kessel AG. de Bruijn DR, et al. Cancer Res. 2006 Oct 1;66(19):9474-82. doi: 10.1158/0008-5472.CAN-05-3726. Cancer Res. 2006. PMID: 17018603 Free article.
122 results
Jump to page